Phase 3 Clinical Study of AK112 for NSCLC Patients
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo
Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or
Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor
Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment